Tarazona-Motes, M.; Albaladejo-Belmonte, M.; Nohales-Alfonso, F.J.; De-Arriba, M.; Garcia-Casado, J.; Alberola-Rubio, J.
Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients’ Characteristics. Int. J. Environ. Res. Public Health 2021, 18, 8783.
https://doi.org/10.3390/ijerph18168783
AMA Style
Tarazona-Motes M, Albaladejo-Belmonte M, Nohales-Alfonso FJ, De-Arriba M, Garcia-Casado J, Alberola-Rubio J.
Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients’ Characteristics. International Journal of Environmental Research and Public Health. 2021; 18(16):8783.
https://doi.org/10.3390/ijerph18168783
Chicago/Turabian Style
Tarazona-Motes, Marta, Monica Albaladejo-Belmonte, Francisco J. Nohales-Alfonso, Maria De-Arriba, Javier Garcia-Casado, and Jose Alberola-Rubio.
2021. "Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients’ Characteristics" International Journal of Environmental Research and Public Health 18, no. 16: 8783.
https://doi.org/10.3390/ijerph18168783
APA Style
Tarazona-Motes, M., Albaladejo-Belmonte, M., Nohales-Alfonso, F. J., De-Arriba, M., Garcia-Casado, J., & Alberola-Rubio, J.
(2021). Treatment of Dyspareunia with Botulinum Neurotoxin Type A: Clinical Improvement and Influence of Patients’ Characteristics. International Journal of Environmental Research and Public Health, 18(16), 8783.
https://doi.org/10.3390/ijerph18168783
